Good morning :)
$
₹
BioLife Solutions Inc

BioLife Solutions Inc

BLFS

NASDAQ
Asset Logo

BioLife Solutions Inc

BLFS

NASDAQ
$38.593.48% (+1.29)
$
₹
$38.593.48% (+1.29)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Medical Instruments & Supplies

Small Cap

With a market cap of $1.9B the stock is ranked 2225

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

39
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

4.39
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$0.99
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

65.38
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

54.35%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 9 analysts reports

Buy
1 analyst
Hold
8 analysts
Sell
0 analyst

Price Upside

-18.97%

Earnings Growth

+219.05%

Rev. Growth

+19.76%

See Detailed Forecast

Company Profile

Company Profile

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Medline Inc. Class A Common Stock
MDLN
M
P/E Ratio
80.07
80.07
1Y Return
16.85%
16.85%
Buy Reco %
85.18
85.18
West Pharmaceutical Services Inc
WST
West Pharmaceutical Services Inc
P/E Ratio
45.77
45.77
1Y Return
45.58%
45.58%
Buy Reco %
93.75
93.75
The Cooper Companies, Inc
COO
The Cooper Companies, Inc
P/E Ratio
21.06
21.06
1Y Return
12.2%
12.2%
Buy Reco %
35.29
35.29
Align Technology Inc
ALGN
Align Technology Inc
P/E Ratio
22.46
22.46
1Y Return
11.26%
11.26%
Buy Reco %
50.00
50.00
Lantheus Holdings Inc
LNTH
Lantheus Holdings Inc
P/E Ratio
24.34
24.34
1Y Return
77.4%
77.4%
Buy Reco %
20.00
20.00
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies -18.97% growth, versus a trailing 3-year CAGR of 42.62%.

2026
Current$38.61Baseline
Analyst Target - 1 year
Target$31.29-18.97%

All values in $

202220232024202520262027$21.59$28.55$35.51Target-18.97%
2026
Current$38.61Baseline
Analyst Target - 1 year
Target$31.29-18.97%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 19.76% growth, versus a trailing 3-year CAGR of 8.07%.

2025
Current$96.21Baseline
Forecast for Dec 2026
High$116.46+21.05%
Average$115.22+19.76%
Low$114.7+19.21%

All values in $ Million

202120222023202420252026119.1576.2368.0182.2596.21Low+19.21%Average+19.76%High+21.05%
2025
Current$96.21Baseline
Forecast for Dec 2026
High$116.46+21.05%
Average$115.22+19.76%
Low$114.7+19.21%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-0.21Baseline
Forecast for Dec 2026
High$0.25+219.05%
Average$0.25+219.05%
Low$0.25+219.05%

All values in $

202120222023202420252026-0.67-1.62-1.06-0.32-0.21Low+219.05%Average+219.05%High+219.05%
2025
Current$-0.21Baseline
Forecast for Dec 2026
High$0.25+219.05%
Average$0.25+219.05%
Low$0.25+219.05%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

28
0.6
18.7
3.5
27.5
1.1
28.4
45.1
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue18.4319.7130.57-3.4223.9425.4228.0618.7827.528.46
Net Income-10.22-20.71-1.7012.45-0.44-15.830.623.531.1845.10
Net Profit Margin-55.44%-105.09%-5.57%-363.87%-1.87%-62.30%2.21%18.81%4.31%158.44%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Instruments & Supplies

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
BioLife Solutions Inc 394.3965.38
Medline Inc. Class A Common Stock80.072.43-
West Pharmaceutical Services Inc45.779.683.21
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare BLFS with any stock or ETF
Compare BLFS with any stock or ETF
Comparing from
BLFS
MDLN
WST
Loading...

Frequently asked questions

  1. BioLife Solutions Inc (BLFS) share price today is $38.59 as of October 6, 2026 at 1:30 AM IST. The stock touched a day high of $0.00 and a day low of $0.00.

  2. BioLife Solutions Inc stock trades on NASDAQ under the ticker symbol BLFS.

  3. BioLife Solutions Inc's market capitalization is $1.88B as of October 6, 2026 at 1:30 AM IST.

  4. BioLife Solutions Inc's price-to-earnings (P/E) ratio is 39 as of November 4, 2026.

  5. BioLife Solutions Inc's price-to-book (P/B) ratio is 4.39 as of November 4, 2026.

  6. Yes, You can buy BioLife Solutions Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy BioLife Solutions Inc shares in three steps: 1. Search BioLife Solutions Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since BioLife Solutions Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in BioLife Solutions Inc (BLFS) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.259 shares at the current price of $38.59.

Loading...